CSL’s Vaccine Shock: Stock Plunges to 7-Year Low Amid Shareholder Revolt
Vaccine Slump Triggers Profit Downgrade and 7-Year Share Low CSL – Australia’s fourth-largest public company – stunned the market by cutting its profit outlook and delaying a major spinoff due to a steep and unexpected decline in flu vaccinations in the United States. In an AGM update on Oct. 28, the biotech revealed that U.S. influenza immunization rates are dropping far more than…